Camber Launches Bexarotene Capsules

Camber Pharmaceuticals, a leader in generic drug approvals and launches, is proud to add Bexarotene Capsules [bex-AR-oh-teen] to its growing portfolio.
Bexarotene Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Bexarotene Capsules (75mg) are available in 100 count bottles.
To learn more about this product, please visit: www.camberpharma.com/bexarotene
Recent articles
- Camber Launches Bexarotene Capsules
- Camber Pharmaceuticals Appoints Scott Hettenhausen as Vice President of Rx Sales
- Camber Launches Spironolactone Oral Suspension
- Camber Launches Metformin Hydrochloride Oral Solution
- Camber Launches Colchicine Capsules
- 24 New Product Launched in the First Half of 2025